The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG. Lancet Oncol. 2014 Dec;15(13):1503-12. doi: 10.1016/S1470-2045(14)71125-8. Epub 2014 Nov 14. PMID: 25456369 [PubMed - in process]
Related Citations

Posted: December 19, 2014

Consumer Report Confirms the MMRF is One of the Best Charities for Your Money

We are so excited to announce that the MMRF has been listed by Consumer Reports as one of the highest-rated charities for the cancer cause. The report on came out right in the middle of one of the most charitable seasons, and warns against giving to a charity without first doing a little homework. READ MORE

Posted: December 17, 2014

Curing myeloma at last: defining criteria and providing the evidence.

Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J.
Blood. 2014 Nov 13;124(20):3043-51. doi: 10.1182/blood-2014-07-552059. Epub 2014 Oct 7.
PMID: 25293776 [PubMed - in process]
Related citations

Posted: November 25, 2014

Page 83 of 87« First...102030...8182838485...Last »